Olema Pharmaceuticals, Inc.(NASDAQ : OLMA)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||1.07%||171.79||0.7%||$1114.12m|
|MRK||Merck & Co., Inc.||1.36%||77.57||0.7%||$779.19m|
|LLY||Eli Lilly & Co.||2.47%||244.38||1.1%||$746.72m|
|BMY||Bristol-Myers Squibb Co.||0.50%||68.30||1.0%||$595.22m|
|NRXP||NRX Pharmaceuticals, Inc.||50.58%||24.77||0.0%||$217.95m|
|CERE||Cerevel Therapeutics Holdings, Inc.||-1.28%||24.67||0.2%||$150.46m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||2.88%||126.46||0.0%||$93.07m|
|OGN||Organon & Co.||-3.66%||29.79||0.0%||$80.48m|
|ANVS||Annovis Bio, Inc.||12.03%||120.00||0.0%||$76.82m|
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.